MX2023004285A - Composicion y metodo para tratar el cancer utilizando una vacuna como primer principio activo terapeutico en combinacion con un segundo principio activo. - Google Patents
Composicion y metodo para tratar el cancer utilizando una vacuna como primer principio activo terapeutico en combinacion con un segundo principio activo.Info
- Publication number
- MX2023004285A MX2023004285A MX2023004285A MX2023004285A MX2023004285A MX 2023004285 A MX2023004285 A MX 2023004285A MX 2023004285 A MX2023004285 A MX 2023004285A MX 2023004285 A MX2023004285 A MX 2023004285A MX 2023004285 A MX2023004285 A MX 2023004285A
- Authority
- MX
- Mexico
- Prior art keywords
- active ingredient
- combination
- composition
- vaccine
- therapueutic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 2
- 229960005486 vaccine Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 229940124551 recombinant vaccine Drugs 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/068,087 US11813329B2 (en) | 2014-10-24 | 2020-10-12 | Method and composition for treating cancer or skin lesion using a vaccine |
PCT/US2021/054622 WO2022081604A1 (fr) | 2020-10-12 | 2021-10-12 | Composition et méthode de traitement du cancer à l'aide d'un vaccin en tant que premier principe actif thérapeutique en combinaison avec un second ingrédient actif |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023004285A true MX2023004285A (es) | 2023-06-19 |
Family
ID=81208565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023004285A MX2023004285A (es) | 2020-10-12 | 2021-10-12 | Composicion y metodo para tratar el cancer utilizando una vacuna como primer principio activo terapeutico en combinacion con un segundo principio activo. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP4225351A1 (fr) |
JP (1) | JP2023546073A (fr) |
KR (1) | KR20230117106A (fr) |
AU (1) | AU2021360676A1 (fr) |
CA (1) | CA3195478A1 (fr) |
CO (1) | CO2023006083A2 (fr) |
CY (1) | CY20232200001T2 (fr) |
DE (1) | DE21880926T1 (fr) |
DK (1) | DK4225351T1 (fr) |
ES (1) | ES2962700T1 (fr) |
FI (1) | FI4225351T1 (fr) |
HU (1) | HUE21880926T1 (fr) |
IL (1) | IL302098A (fr) |
MX (1) | MX2023004285A (fr) |
PL (1) | PL4225351T1 (fr) |
WO (1) | WO2022081604A1 (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10162480A1 (de) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
US9504657B2 (en) * | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
CA2871774C (fr) * | 2012-04-26 | 2021-05-18 | Sentient Lifesciences, Inc. | Utilisation de n-acetylcysteine amide dans le traitement de maladies et de lesions |
US10799574B2 (en) * | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
EA201891965A1 (ru) * | 2016-04-01 | 2019-04-30 | Кайт Фарма, Инк. | Химерные рецепторы антигенов и т-клеточные рецепторы и способы их применения |
WO2017177137A1 (fr) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Compositions de lymphocytes t récepteurs d'antigènes chimériques |
-
2021
- 2021-10-12 JP JP2023522489A patent/JP2023546073A/ja active Pending
- 2021-10-12 PL PL21880926.7T patent/PL4225351T1/pl unknown
- 2021-10-12 FI FIEP21880926.7T patent/FI4225351T1/fi unknown
- 2021-10-12 AU AU2021360676A patent/AU2021360676A1/en active Pending
- 2021-10-12 HU HUE21880926A patent/HUE21880926T1/hu unknown
- 2021-10-12 MX MX2023004285A patent/MX2023004285A/es unknown
- 2021-10-12 DK DK21880926.7T patent/DK4225351T1/da unknown
- 2021-10-12 WO PCT/US2021/054622 patent/WO2022081604A1/fr active Application Filing
- 2021-10-12 EP EP21880926.7A patent/EP4225351A1/fr active Pending
- 2021-10-12 DE DE21880926.7T patent/DE21880926T1/de active Pending
- 2021-10-12 CA CA3195478A patent/CA3195478A1/fr active Pending
- 2021-10-12 KR KR1020237016232A patent/KR20230117106A/ko unknown
- 2021-10-12 ES ES21880926T patent/ES2962700T1/es active Pending
- 2021-10-12 IL IL302098A patent/IL302098A/en unknown
-
2023
- 2023-05-12 CO CONC2023/0006083A patent/CO2023006083A2/es unknown
- 2023-10-19 CY CY20232200001T patent/CY20232200001T2/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK4225351T1 (da) | 2023-10-23 |
IL302098A (en) | 2023-06-01 |
JP2023546073A (ja) | 2023-11-01 |
HUE21880926T1 (hu) | 2024-04-28 |
ES2962700T1 (es) | 2024-03-20 |
KR20230117106A (ko) | 2023-08-07 |
FI4225351T1 (fi) | 2023-10-20 |
WO2022081604A1 (fr) | 2022-04-21 |
CY20232200001T2 (el) | 2024-02-16 |
PL4225351T1 (pl) | 2023-12-11 |
DE21880926T1 (de) | 2024-01-11 |
CA3195478A1 (fr) | 2022-04-21 |
AU2021360676A1 (en) | 2023-06-15 |
CO2023006083A2 (es) | 2023-08-18 |
EP4225351A1 (fr) | 2023-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Walk et al. | Cold atmospheric plasma for the ablative treatment of neuroblastoma | |
Perdanasari et al. | Recent developments in the use of intralesional injections keloid treatment | |
Thappa et al. | Evolving role of immunotherapy in the treatment of refractory warts | |
Good et al. | Intralesional agents in the management of cutaneous malignancy: a review | |
HUP0303976A2 (hu) | Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásával | |
El-Khalawany et al. | Immunotherapy of viral warts: myth and reality | |
Galiczynski et al. | Nonsurgical treatment of nonmelanoma skin cancer | |
PH12021551023A1 (en) | Methods for shrinking pituitary tumors | |
Abbas et al. | Management of Anal Cancer in 2010-Part 2: Current Treatment Standards and Future Directions | |
WO2022012635A9 (fr) | Composition pharmaceutique et son utilisation | |
MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
Gong et al. | Needle‐free injection of 5‐aminolevulinic acid in photodynamic therapy for the treatment of non‐melanoma skin cancer | |
Sparling et al. | Imiquimod for plantar and periungual warts | |
Levenberg et al. | Potentials for implementing pressure‐controlled jet injection in management of keloids with intralesional 5FU and corticosteroids | |
MX2023004285A (es) | Composicion y metodo para tratar el cancer utilizando una vacuna como primer principio activo terapeutico en combinacion con un segundo principio activo. | |
Tadmor et al. | A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome | |
IL297502A (en) | A method for treating cervical cancer | |
KR20130009590A (ko) | 항사마귀 약학적 조성물 및 사마귀 치료를 위한 방법 | |
MX2018010338A (es) | Metodo y composicion para tratamiento del cancer o una lesion de la piel utilizando una vacuna. | |
Berman et al. | Treatment of warts | |
MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
CN105943595B (zh) | 一种治疗化疗致手足综合征、靶向治疗致手足皮肤反应的药物及其制备方法 | |
Maghrabi et al. | Management of Keloid and Hypertrophic Scar: Role of Nutrition, Drugs, Cryotherapy and Phototherapy | |
PH12017500754A1 (en) | Cancer and skin lesion treatment | |
Rizvi et al. | Keyhole limpet hemocyanin: an effective adjunct against melanoma in vivo |